BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 26888822)

  • 1. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
    Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
    BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
    Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
    BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
    Liu J; Li L; Deng K; Xu C; Busse JW; Vandvik PO; Li S; Guyatt GH; Sun X
    BMJ; 2017 Jun; 357():j2499. PubMed ID: 28596247
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
    Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
    BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Scirica BM; Im K; Murphy SA; Kuder JF; Rodriguez DA; Lopes RD; Green JB; Ruff CT; Sabatine MS
    Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
    Guo WQ; Li L; Su Q; Dai WR; Ye ZL
    Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
    Sano M
    J Cardiol; 2019 Jan; 73(1):28-32. PubMed ID: 30318179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.
    Xu S; Zhang X; Tang L; Zhang F; Tong N
    Postgrad Med; 2017 Mar; 129(2):205-215. PubMed ID: 27813442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.